Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody
286€ (100 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx129227
tested applications
WB, IHC, IF/ICC
Description
Breast Cancer Anti-Estrogen Resistance 3 Antibody is a Rabbit Polyclonal against Breast Cancer Anti-Estrogen Resistance 3.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Polyclonal |
| Conjugation | Unconjugated |
| Purification | Purified by antigen-specific affinity chromatography, followed by Protein A affinity chromatography. |
| Size 1 | 100 µl |
| Size 2 | 200 µl |
| Size 3 | 1 ml |
| Form | Liquid |
| Tested Applications | WB, IHC, IF/ICC |
| Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
| Availability | Shipped within 5-7 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | O75815 |
| Alias | BCAR3, NSP2, SH2D3B, breast cancer anti-estrogen resistance 3, AND-34, NSP family adaptor protein, BCAR3 adaptor protein, NSP family member, MIG7 |
| Background | Antibody anti-BCAR3 |
| Status | RUO |
Descripción
BCAR3, also known as Breast Cancer Anti-Estrogen Resistance Protein 3, is involved in the development of resistance to anti-estrogen therapies in breast cancer, much like its family members BCAR1 and BCAR2. BCAR3 has been shown to participate in signaling pathways that affect cell survival and migration. This protein is often implicated in the progression of cancer cells from an estrogen-dependent to an estrogen-independent state, allowing them to proliferate and survive despite the presence of estrogen inhibitors. BCAR3’s interaction with other molecular players in cell signaling, such as those controlling cytoskeletal reorganization, further contributes to cancer cell invasion and metastasis. Targeting BCAR3 may offer new therapeutic approaches for overcoming resistance in estrogen receptor-positive breast cancer, providing more effective treatments for patients with advanced disease. Its role in cancer progression and therapy resistance makes BCAR3 an important subject of ongoing research in oncology.
Related Products
Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Antibody
Breast Cancer Anti-Estrogen Resistance 3 Antibody is a Rabbit Polyclonal against Breast Cancer Anti-Estrogen Resistance 3.
Ver Producto
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) ELISA Kit is an ELISA Kit for the in vitro quantitative measurement of Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) concentrations in serum, plasma, tissue homogenates and other biological fluids. This assay has high sensitivity and excellent specificity for detection of Breast Cancer Anti-Estrogen Resistance 3 (BCAR3)
Ver Producto
Human Breast Cancer Anti-Estrogen Resistance 3 (BCAR3) Protein
Breast Cancer Anti-Estrogen Resistance 3 Protein is a recombinant Human protein expressed in E. coli.
Ver Producto